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The average time between infection with human immunodeficiency virus (HIV) and development of acquired
immune deficiency syndrome is ∼8 years. However, progression rates vary widely, depending on several
determinants, including HIV-specific immunity, host genetic factors, and virulence of the infecting strain. In
untreated HIV-infected patients with different progression rates, we examined HIV-specific T cell responses
in combination with host genetic markers, such as chemokine/chemokine-receptor (CCR) polymorphisms and
human leukocyte antigen (HLA) genotypes. HIV-specific CD4+ T cell responses and, to a lesser extent, HIV-
specific CD8+ T cell responses were inversely correlated with progression rate. Slower progression was not
related to polymorphisms in CCR genes, HLA genotype, or GB virus C coinfection. These data suggest that
HIV-specific T cell responses are involved in protecting the host from disease progression.
Disease-progression rates, between infection with HIV
and the development of AIDS, vary greatly; although
the median time is 8–10 years [1], this interval can vary
from as little as 2–3 years (in subjects in whom disease
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progression is rapid) to 15–20 years or more (in subjects
in whom disease progression is either absent or slow)
[2]. Definitions of long-term nonprogression of disease
and short-term progression of disease differ substan-
tially [2] and depend on criteria such as the decline in
CD4+ T cell count, the absolute CD4+ T cell count, and
the HIV RNA level; however, it is clear that the disease-
progression rate is determined by several factors, in-
cluding HIV-specific cellular immune responses, host
genetic factors, and viral factors.
The role that the HIV-specific cellular immune re-
sponse plays in the constraint of HIV replication is still
a matter of debate [3, 4]. In acute HIV infection, in-
duction of HIV-specific CD8+ T cell responses coincides
with the control of viral replication [5–7]. Immune
escape due to sequence variation in viral T cell epitopes
is associated with increases in HIV RNA levels and
implies that CD8+ T cells play a central role [8–11].
Furthermore, depletion of CD8+ T cells in monkeys
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infected with simian immunodeficiency virus has been reported
to result in a rapid increase in viral replication [12].
In chronic HIV infection, inverse correlations between HIV
RNA load in plasma (pVL) and HIV-specific T cell frequencies
have been observed [13]. These initial observations have not
been confirmed by subsequent studies examining the frequen-
cies of HIV-specific CD8+ T cells in relation to viremia [14–
18]; however, qualitative differences in antigen-specific CD8+
T cell responses of similar magnitude may play an important
role in determining the efficiency with which viral replication
is contained [14].
CD4+ T cells, the main targets for HIV infection, play a key
role in orchestrating cellular immune responses. HIV-specific
CD4+ T cell counts are higher in patients with long-term non-
progression of disease than in patients with progression of dis-
ease, but there is substantial overlap [19]. Especially in chronic
HIV infection, strong HIV-specific CD4+ T cell responses cor-
relate with lower viral-replication levels and have been impli-
cated as being beneficial for the maintenance of functional
CD8+ T cell responses [20–22].
Multiple host genes influence HIV’s progression rate (re-
viewed in [23–25]) and also may contribute to the immune
response; for example, a number of major-histocompatibility-
complex class I alleles and polymorphisms within the CCR
genes, such as CCR5, CCR2, SDF-1, CX3CR1, and RANTES,
influence disease-progression rates. However, it should be noted
that not all studies have reached similar conclusions regarding
the effects of distinct polymorphisms [26, 27]. Additional fac-
tors that have been reported to affect the course of HIV disease
include coinfections with GB virus C [28].
Viral factors can also affect the outcome of infection. Strains
of HIV harboring unusual polymorphisms may explain the
benign course of disease observed in a number of subjects with
disease progression that is either slow or absent. HIV variants
that are defective in the Nef gene [29] or that have either
extension of the V2 region [30] or mutations in the gp41 trans-
membrane region [31] have been associated with slower disease
progression.
The relatively few studies that have attempted to examine
multiple parameters simultaneously that could contribute to
disease progression within a single cohort of infected individ-
uals have reached different conclusions [26, 27, 32]. In the
present study, we analyzed a number of variables in a cohort
of HIV-infected patients, in an attempt to dissect the relative
contribution that these factors make to disease progression.
PATIENTS, MATERIALS, AND METHODS
Patients. We prospectively recruited and examined (1) 28
(patients 1–28) chronically HIV-infected white patients with a
broad range of progression rates who were not being treated
with antiretroviral therapy (ART) and (2) 10 patients (patients
29–38) being treated with ART (table 1). Accordingly, our in-
clusion criteria were as follows: (1) untreated patients had to
have both documented HIV infection for 2–17 years and CD4+
T cell counts 1250 cells/mL, with longitudinal clinical data doc-
umenting CD4+ T cell count and pVL; (2) ART-treated patients
had to have HIV RNA levels and CD4+ T cell counts that
matched those in untreated patients with either no or slow
disease progression; and (3) all patients had to be 18–75 years
of age. We included only patients with HIV clade B infections
(except for patients 1, 6, and 21, whose HIV clade could not
be determined, because of low pVL). The study was approved
by the Ethical Committee of the University Hospital of Zurich,
Switzerland.
Quantification of pVL. pVL was quantified by the ultra-
sensitive Amplicor Monitortest, version 1.5 (Roche Diagnostics).
The lower limit of detection was 50 copies of HIV RNA/mL.
HLA genotyping. Genotyping was performed by use of either
a commercially available kit, Cyclerplate System Protrans HLA A*/
B*/DRB1* (Medizinische Diagnostische Produkte GMBH, En-
dotell AG) or polymerase chain reaction (PCR) with sequence-
specific primers (Lymphotype ABC144; Biotest Schweiz AG) [33].
CCR genotyping. To analyze the CCR5D32-deletion poly-
morphism, the region encompassing the 32-nt deletion in CCR5
was amplified, and the 2 alleles were separated by PAGE [34].
Allelic variants of CCR2 V64I, CCR 559029G/A, and SDF-1 3′G/
A were analyzed by 3 tetraprimer PCR assays [35]. In brief, for
each assay, 4 primers were combined in a single tube, for initial
amplification of the gene locus and subsequent allele-specific am-
plification. Products of the PCR amplification were separated by
agarose-gel electrophoresis, for allelic discrimination.
GB virus C RNA. GB virus C RNA was extracted from
plasma by use of the QIAamp Viral RNA Mini Kit (Qiagen),
according to the manufacturer’s instructions. Extracted RNA
was reverse transcribed and amplified by nested PCR with prim-
ers specific for GB virus C. PCR products were quantified by
gel electrophoresis [36] in which the lower limit of detection
was 50–500 copies/mL.
HIV-specific T cells. Comprehensive analysis of HIV-spe-
cific CD8+ T cell responses was performed directly ex vivo by
interferon (IFN)–g ELISpot analysis, as described elsewhere
[37]. In brief, cryopreserved peripheral-blood lymphocytes
(PBLs) were screened with pooled overlapping (by 10 amino
acids) peptides, in which each peptide had a final concentration
of 5 mg/mL and was 20 amino acid residues long. Peptides
spanned the HIV reverse transcriptase, envelope (Env), p24
viral capsid antigen (p24 Gag), p17 Gag, and the accessory HIV
proteins—Nef, Tat, and Rev (National Institute for Biological
Standards and Control). Each peptide pool comprised 10 in-
dividual peptides. Phytohemagglutinin (PHA) was always in-
cluded as a positive control, and the use of medium alone
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Figure 1. HIV p24-specific CD4+ (A) and HIV-specific CD8+ (B) T cell frequencies, in untreated patients. nd, not determined.
allowed nonspecific background to be determined. HIV-specific
CD4+ T cell counts were determined ex vivo by IFN-g ELISpot
analysis; PBLs were depleted of CD8+ T cells by anti-CD8+
monoclonal antibody conjugated to magnetic beads (Dynal
UK) before stimulation with overlapping pooled peptides (20-
mer peptides overlapping by 10 amino acids) that spanned the
full-length HIV p24 protein (5 mg/mL [National Institute for
Biological Standards and Control]) [37].
The HIV-unrelated recall antigen streptokinase/streptodor-
nase (SK/SD) (200 U/mL [Lederle]) and nonspecific PHA stim-
ulation (5 mg/mL) were used as positive controls, and medium
alone was used as the negative control. Results were expressed
as the number of specific spot-forming cells (SFCs) per 106
CD8+ T cell–depleted PBLs. Before normalization, background
values were subtracted from the specific response.
A positive response was defined as one that was 13 SD above
background. Spot quantification was automated and standard-
ized by use of an ELISpot plate reader, software version 2.1
(Autoimmun Diagnostika). All assays were performed in
duplicate.
Statistics. Data were analyzed by either SPSS 11.0 linear
regression or Spearman’s rank correlations. The Mann-Whitney
U test and T test were used for comparative analysis of the
groups of untreated and ART-treated patients.
RESULTS
HIV-specific T cell responses correlate with disease-progression
rates in untreated patients. We examined a cohort of 28
chronically HIV-infected, antiretroviral-naive patients with
documented varying course of pVL and CD4+ T cell count over
time (table 1). To examine HIV-specific CD8+ T cell frequencies,
PBLs were screened by IFN-g ELISpot analysis with overlapping
peptides spanning the HIV proteins Env, Gag, Pol, Nef, Tat,
and Rev. We determined the composition of the HIV-specific
CD8+ T cell response to each individual protein. Most of the
responses were directed against the HIV Gag p24, Nef, and Pol
proteins (figure 1B). The magnitude of the total response (de-
fined as the sum of all responses to individual pools) correlated
with the number of recognized pools per patient (figure 2A),
indicating that the greater the HIV-specific CD8+ T cell count,
the broader the recognition profile. These findings corroborate
previously reported observations [17, 18].
To determine the HIV-specific CD4+ T cell frequencies, CD8-
depleted PBLs were stimulated with the pooled overlapping
peptides spanning HIV Gag p24 (figure 1). The results showed
that, in general, patients with high HIV-specific CD8+ T cell
frequencies also exhibited detectable or substantial HIV-specific
CD4+ T cell frequencies (figure 2B); indeed, the frequencies of
these 2 types of cells were positively correlated (figure 2B).
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Figure 2. A, Total HIV-specific CD8+ T cell response and no. of recognized
peptide pools, in 28 untreated patients. The magnitude of the total HIV-
specific CD8+ T cell response (defined as the sum of individual responses)
correlated with the no. of recognized peptide pools. B, HIV-specific CD4+
and HIV-specific CD8+ T cell frequencies. The log of the total HIV-specific
CD8+ T cell frequencies correlates with the log of the HIV p24-specific CD4+
T cell frequencies. Each black dot () represents data from an individual
patient. P and r values for linear regression are shown.
The aforementioned assessment of CD8+ T cell frequencies
included CD4+ T cell responses, because CD4+ T cells were not
depleted before stimulation. Herein, we have referred to this
total response as “CD8+ T cell response” because its contri-
bution to the total response is 20–1000-fold greater than that
of the CD4+ T cell response. The positive correlation between
the HIV-specific CD8+ T cell response and the p24-specific
CD4+ T cell response also held when the p24-specific CD4+ T
cell response was subtracted from the total response prior to
the analysis ( ; data not shown).Pp .007
We next sought to correlate, in our cohort of HIV-infected
patients, the magnitude of the immune responses to the dif-
ferent disease-progression rates. The slope for CD4+ T cells is
very powerful for the prediction of the disease-progression rate
[38]. Furthermore, integration of both HIV RNA and CD4+ T
cell count into a single parameter provides a better predictor
of disease progression than does either measurement alone [39,
40]. For each patient, we calculated 2 parameters that reflected
the disease-progression rate. First, regression analysis of all
available total CD4+ T cell counts before the analysis yielded a
slope that characterized the yearly change in CD4+ T cell count
until the time of analysis. Second, we refined this parameter
by integrating the evolution of pVL into it; at each time point,
the ratio of CD4+ T cell count to the corresponding log pVL
was used for regression analysis, to yield the yearly change in
total CD4+ T cell count/log pVL (hereafter termed “normalized
yearly change in CD4+ T cell count”). A median of 10 (range,
4–20) values each for CD4+ T cell count and for HIV RNA
were available for the calculation of the slopes.
We then compared the 2 slopes to the magnitude of each
patient’s HIV-specific T cell response (figure 3). Although it
was not statistically significant, there was an inverse correlation
between the total HIV-specific CD8+ T cell frequencies and the
normalized yearly change in CD4+ T cell count ( ; fig-Pp .054
ure 3C). In contrast, no correlation, either direct or inverse,
was observed between either the yearly change in CD4+ T cell
count or the normalized yearly change in CD4+ T cell count
and the total CD8+ T cell count ( and , re-Pp .969 Pp .767
spectively) or between the total HIV-specific CD8+ T cell count
and pVL ( ).Pp .137
The normalized yearly change in CD4+ T cell count was
inversely correlated with the HIV p24-specific CD4+ T cell fre-
quencies (figure 3D; ) but not with the HIV-unrelatedPp .003
antigen SK/SD-specific CD4+ T cell frequencies ( ). NoPp .723
correlation between actual pVL and the HIV p24-specific CD4+
T cell frequencies was observed ( ).Pp .374
These results indicate that stronger and broader HIV-specific
CD8+ T cell responses and greater HIV-specific CD4+ T cell
frequencies were associated with slower disease-progression rate
as defined by the normalized yearly change in CD4+ T cell
count before the analysis. In contrast, no relation between the
duration of infection and the magnitude of the HIV-specific T
cell response was observed (data not shown).
Influence of host factors on time course of HIV infection.
Various host genetic factors are associated with distinct HIV
progression rates [23, 24]. We therefore analyzed whether, in
our cohort of HIV-infected patients, our parameters for disease
progression (i.e., yearly change in CD4+ T cell count and yearly
normalized change in CD4+ T cell count) were correlated with
either different host genetic factors or coinfection with GB virus
C. We used Spearman’s rank correlations to analyze the fol-
lowing host factors:
1. HLA class I genotype: Based on the HLA genotype of
each patient, a relative risk hazard was calculated on the basis
of the relative HLA hazard values reported in a study by O’Brien
et al. [41] (see details in the footnotes to table 2). Only HLA
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Figure 3. Correlations between disease progression and HIV-specific CD4+ and HIV-specific CD8+ T cell frequencies, in 28 untreated patients. A, Yearly
decreases in CD4+ T cell counts, showing a trend toward an inverse correlation with the log of the total HIV-specific CD8+ T cell frequencies. Total HIV-
specific CD8+ T cell frequencies are the sum of all responses measured against individual peptide pools, and yearly change in CD4+ T cell counts was
calculated by regression through all available measurements of CD4+ T cell counts. B, Yearly change in CD4+ T cell counts, which are not correlated with
the log of HIV p24-specific CD4+ T cell frequencies. C, Yearly change in CD4+ T cell count/log of virus load in plasma (log pVL), showing a trend toward
an inverse correlation with the log of total HIV-specific CD8+ T cell frequencies. The yearly change in CD4+ T cell count/log pVL was calculated by regression
through the quotients of total CD4+ T cell count and log pVL. D, Yearly change in CD4+ T cell count/log pVL, which is inversely correlated with the log
of HIV p24-specific CD4+ T cell frequencies. Each black dot () represents data from an individual patient. P and r values for linear regression are shown.
PBLs, peripheral-blood lymphocytes; SFCs, spot-forming cells.
alleles B*58, B*27, B*57, B*51, A*11, A*68, B*35, and B*53
(all of which have a significant relative hazard) were used for
the calculation. No correlation between HLA genotype and
disease-progression rate was found (table 2).
2. CCR2/CCR5 polymorphism: Based on the CCR2-
CCR5 genotype of each patient, a relative risk hazard was cal-
culated on the basis of the relative hazard values reported in a
study by Ioannidis et al. [42] (see details in the footnotes to
table 2). No correlation between the combined CCR2-CCR5
genotype and disease-progression rate was found (table 2).
3. CCR2/CCR5 polymorphism and coinfection with GB
virus C: We combined the relative hazard values calculated in
item 2 with the relative risk factor inferred on the basis of
coinfection with GB virus C, as reported by Xiang et al. [28]
(see details in the footnotes to table 2). No correlation between
the combined CCR2-CCR5 genotype plus GB virus C coinfec-
tion and disease-progression rate was found (table 2).
4. CCR2/CCR5 polymorphism, coinfection with GB virus
C, and HLA genotype: We combined all the relative hazard
values calculated in items 1 and 3; no correlation between this
combined relative hazard value and disease-progression rate
was found (table 2).
In summary, we found no correlation between our measures
of disease-progression rate and either host genetic factors or
GB virus C coinfection; however, because the size of our cohort
of HIV-infected patients is very small compared with those
normally used for genetic analyses, our results do not exclude
the possibility that host genetic factors are involved in disease
progression.
HIV-specific T cell responses in untreated subjects and in
treated patients who had comparable viremia and CD4+ and
CD8+ T cell counts. We hypothesized that the association
between stronger and broader HIV-specific CD4+ and HIV-
specific CD8+ T cell responses and a slower disease-progression
rate was a causal relationship and not just a consequence of a
generally lower pVL in patients with slower disease progression.
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Figure 4. HIV-specific CD4+ and HIV-specific CD8+ T cell responses, in untreated patients (group 1) and in patients being treated with antiretroviral
therapy (group 2) who had comparable plasma viremia and total CD4+ and total CD8+ T cell counts. The gray boxes denote interquartile ranges; the black
bars denote medians; the whiskers extend to adjacent values, and the asterisks denote outliers. A, Total HIV-specific CD8+ T cell frequencies. B, No. of
peptide pools inducing a positive CD8+ T cell response. C, HIV p24-specific CD4+ T cell frequencies. D, Virus load in plasma. E, Total CD4+ T cell counts.
F, Total CD8+ T cell counts.
Therefore, we compared the HIV-specific CD8+ T cell fre-
quencies in 10 untreated subjects (individual 1, 2, 3, 5, 9, 11–
13, 21, and 26) versus those in 10 ART-treated patients (in-
dividuals 29–38) who had comparable plasma viremia and total
CD4+ and total CD8+ T cell counts (figure 4). The total HIV-
specific CD8+ T cell frequencies, the number of recognized
peptide pools, and the HIV p24-specific CD4+ T cell frequencies
in the untreated group were significantly higher than those in
the treated group ( ; figure 4), despite the absencePp .001–.006
of any significant difference in the total CD4+ T cell counts.
This lends support to speculation that stronger HIV-specific
cellular immunity in untreated patients is at least partly re-
sponsible for this clinical phenotype and that it is not merely
a consequence of lower viral replication. Alternatively, the most
drug-resistant and, therefore, probably “less-fit” virus that exists
in ART-treated patients with detectable viremia may induce
fewer specific immune responses that are of lesser magnitude.
DISCUSSION
In the present study, we have examined the HIV-specific cellular
immune response and host genetic factors in a cohort of HIV-
infected patients. To reduce the heterogeneity in this cohort,
we included only patients with a follow-up of 2 years and
excluded all patients infected with documented HIV strains
other than clade B. We sought to define individual disease-
progression rates on the basis of the evolution of CD4+ T cell
count and pVL. For each patient, we calculated a slope through
all available CD4+/pVL ratios. We found that HIV-specific CD4+
T cell responses and, to a lesser extent, HIV-specific CD8+ T
cell responses were inversely correlated with disease-progression
rate defined as the rate of CD4+ T cell change in relation to
pVL. No correlations between the HIV-specific cellular immune
response and either the HIV RNA level or the total CD4+ T
cell count at the time of analysis were seen. However, we did
observe that the yearly change in the total CD4+ T cell count
was correlated with pVL at the time of analysis (i.e., the higher
the pVL at the time of analysis, the greater the slope of the
change in total CD4+ T cell count before analysis ( ).Pp .002
The cellular immune response in chronic HIV infection is
the product of past interactions between HIV and the immune
system, rather than the result of an immediate event. Thus,
comparisons between the decline in CD4+ T cell count (i.e.,
yearly change in CD4+ T cell count) and HIV-specific cellular
immune response seem more appropriate than correlations
with a single CD4+ T cell count. The slope for CD4+ T cells is
very powerful for predicting the disease-progression rate [38].
Integration of both the HIV RNA level and the CD4+ T cell
count into a single parameter provides a better predictor of
disease progression than does the use of either measurement
alone [40]. In consideration of this, we sought to integrate the
evolution of both CD4+ T cell count and pVL into one param-
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eter. To do this, we calculated the ratio between the absolute
CD4+ T cell count and the log of HIV RNA at each available
time point for each patient. Regression through these data
points yielded a slope that correlated inversely with the HIV-
specific CD4+ T cell frequencies and that showed a tendency
toward an inverse correlation with the HIV-specific CD8+ T
cell frequencies. We conclude that the evolution of viremia and
CD4+ T cell count before the time of analysis is related to the
magnitude of the HIV-specific cellular immune response. Thus,
an efficient HIV-specific cellular immune response is charac-
teristic of patients with either stable CD4+ T cell counts or
stable HIV RNA levels, and a weak or absent HIV-specific cel-
lular immune response is characteristic of patients with either
increasing viremia or a dramatic decrease in CD4+ T cell count.
Clearly, factors other than the magnitude of the HIV-specific
cellular immune response are involved in disease progression.
For example, patient 6 had no detectable HIV RNA during the
preceding 2 years and had no detectable HIV-specific cellular
immune response; in contrast, patients 1 and 2 also had no
detectable HIV RNA but did have prominent HIV-specific cel-
lular immune responses (respective CD8+ T cell responses,
16,421 SFCs/106 PBLs and 12,970 SFCs/106 PBLs). Thus, mech-
anisms governing the disease-progression rate in patients are
most likely very diverse. HIV-specific cellular immunity might
be crucial in some patients, but other factors might be decisive
in others.
Various host genetic factors are associated with distinct HIV
disease–progression rates [23, 24]. Convincing data exist for
the involvement of certain HLA class I genotypes (reviewed in
[25]) and polymorphisms of CCR5 and CCR2 [42]. We sought
to assess these host genetic factors in our cohort of HIV-infected
patients and to determine whether disease progression is better
correlated with these factors or with the HIV-specific cellular
immune response. Because coinfection with GB virus C is pre-
dictive of longer survival [28], we also looked at this parameter.
Because our cohort of HIV-infected patients was small, our
results must be considered with caution. Slower disease pro-
gression, as defined by either the yearly change in CD4+ T cell
count or the yearly normalized change in CD4+ T cell count,
was not related to polymorphisms in CCR genes, to HLA alleles,
or to coinfection with GB virus C.
We also compared the HIV-specific cellular immune response
in untreated patients with that in ART-treated patients. The 2
groups of patients were matched for their absolute CD4+ T cell
counts and HIV RNA levels at the time of their recruitment.
We found that HIV-specific CD4+ T cell frequencies and HIV-
specific CD8+ T cell frequencies were substantial in all patients
with detectable viremia; however, the virus-specific T cell fre-
quencies were significantly higher in the untreated patients than
in the ART-treated patients. This suggests that the magnitude
of the HIV-specific immune response is not merely reflecting
antigenic drive. However, the nadir of the absolute CD4+ T cell
count in the ART-treated patients was very low, with a median
of 34 cells/mL (range, 0–609 cells/mL), before the initiation of
ART. Because of the marked decrease in CD4+ T cell counts in
these patients, the immune system may have been irreversibly
damaged [4].
In summary, we have ranked untreated patients within a
spectrum of disease progression, according to the evolution of
their total CD4+ T cell count and pVL. Using this approach,
we have found that the magnitude of the HIV-specific cellular
immune response is inversely related to the previous evolution
of total CD4+ T cell count and pVL. These findings add weight
to the argument that HIV-specific cellular immunity is
protective.
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